Literature DB >> 1475232

Pharmacokinetic disposition of multiple-dose transdermal nicotine in healthy adult smokers.

G M Kochak1, J X Sun, R L Choi, A J Piraino.   

Abstract

The pharmacokinetics and cardiovascular effects of nicotine and its major metabolite, cotinine, were characterized during repeated once-daily application for 5 days of a 30-cm2 nicotine transdermal system, Nicotine TTS (Habitrol), to nine healthy, black, adult, male smokers. Subjects abstained from smoking throughout the study. Pharmacokinetic analysis indicated that nicotine was delivered from Nicotine TTS for the 24-hr application period averaging 0.76 mg/cm2/24 hr, and at a relatively constant rate compared to other modes of drug administration. The transdermal clearance of nicotine, 1351 ml/min, coincided with reported values following intravenous nicotine administration; however, the terminal-phase half-life, 5.0 hr, did not. An analysis of the components of variance contributing to the variability in nicotine delivery from repetitive application of Nicotine TTS indicated that the in vivo transdermal permeation of nicotine is rate limited by both the device and the intrinsic skin conductivity. Clinical cardiovascular side effects were negligible as an apparent result of subclinical vasopressive nicotine concentrations, although drug activity with regard to other effects was manifested.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1475232     DOI: 10.1023/a:1015862930096

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  9 in total

1.  Transdermal nicotine facilitates smoking cessation.

Authors:  J E Rose; E D Levin; F M Behm; C Adivi; C Schur
Journal:  Clin Pharmacol Ther       Date:  1990-03       Impact factor: 6.875

2.  Clinical and pharmacokinetic properties of a transdermal nicotine patch.

Authors:  S C Mulligan; J G Masterson; J G Devane; J G Kelly
Journal:  Clin Pharmacol Ther       Date:  1990-03       Impact factor: 6.875

3.  Intra- and intersubject variability: mixed-effects statistical analysis of repeated doses of an angiotensin converting enzyme inhibitor, CGS 16617.

Authors:  G M Kochak; R A Smith; R L Choi; V John; V Tipnis; F Honc; J K deSilva; D J Weidler
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

4.  Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids.

Authors:  P Jacob; M Wilson; N L Benowitz
Journal:  J Chromatogr       Date:  1981-01-02

5.  Interindividual variability in the metabolism and cardiovascular effects of nicotine in man.

Authors:  N L Benowitz; P Jacob; R T Jones; J Rosenberg
Journal:  J Pharmacol Exp Ther       Date:  1982-05       Impact factor: 4.030

6.  Plasma nicotine levels after cigarette smoking and chewing nicotine gum.

Authors:  M A Russell; C Feyerabend; P V Cole
Journal:  Br Med J       Date:  1976-05-01

7.  Human pharmacological investigations of a transdermal nicotine system.

Authors:  P Müller; P R Imhof; D Mauli; D Milovanovic
Journal:  Methods Find Exp Clin Pharmacol       Date:  1989-03

8.  Cotinine disposition and effects.

Authors:  N L Benowitz; F Kuyt; P Jacob; R T Jones; A L Osman
Journal:  Clin Pharmacol Ther       Date:  1983-11       Impact factor: 6.875

9.  Effectiveness of a transdermal nicotine system in smoking cessation studies.

Authors:  T Abelin; R Ehrsam; A Bühler-Reichert; P R Imhof; P Müller; A Thommen; K Vesanen
Journal:  Methods Find Exp Clin Pharmacol       Date:  1989-03
  9 in total
  1 in total

Review 1.  Optimisation of treatment by applying programmable rate-controlled drug delivery technology.

Authors:  Yie W Chien; Senshang Lin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.